Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
1992 1
1993 1
1995 1
2003 2
2004 2
2005 1
2010 1
2011 3
2012 7
2013 1
2014 2
2015 2
2016 1
2017 1
2019 2
2020 1
Text availability
Article attribute
Article type
Publication date

Search Results

29 results
Results by year
Filters applied: . Clear all
Page 1
Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.
Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, Yang M, Raghupathi K, Novas M, Sweetser MT, Viglietta V, Dawson KT; CONFIRM Study Investigators. Fox RJ, et al. N Engl J Med. 2012 Sep 20;367(12):1087-97. doi: 10.1056/NEJMoa1206328. N Engl J Med. 2012. PMID: 22992072 Free article. Clinical Trial.
Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.
Calabresi PA, Kieseier BC, Arnold DL, Balcer LJ, Boyko A, Pelletier J, Liu S, Zhu Y, Seddighzadeh A, Hung S, Deykin A; ADVANCE Study Investigators. Calabresi PA, et al. Lancet Neurol. 2014 Jul;13(7):657-65. doi: 10.1016/S1474-4422(14)70068-7. Epub 2014 Apr 30. Lancet Neurol. 2014. PMID: 24794721 Clinical Trial.
Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial.
Cadavid D, Mellion M, Hupperts R, Edwards KR, Calabresi PA, Drulović J, Giovannoni G, Hartung HP, Arnold DL, Fisher E, Rudick R, Mi S, Chai Y, Li J, Zhang Y, Cheng W, Xu L, Zhu B, Green SM, Chang I, Deykin A, Sheikh SI; SYNERGY study investigators. Cadavid D, et al. Lancet Neurol. 2019 Sep;18(9):845-856. doi: 10.1016/S1474-4422(19)30137-1. Epub 2019 Jul 5. Lancet Neurol. 2019. PMID: 31285147
Skeletal muscle findings in experimental autoimmune encephalomyelitis.
Luque E, Ruz-Caracuel I, Medina FJ, Leiva-Cepas F, Agüera E, Sánchez-López F, Lillo R, Aguilar-Luque M, Jimena I, Túnez I, Peña J. Luque E, et al. Among authors: Sanchez-Lopez F. Pathol Res Pract. 2015 Jul;211(7):493-504. doi: 10.1016/j.prp.2015.02.004. Epub 2015 Feb 17. Pathol Res Pract. 2015. PMID: 25769878
Natalizumab Modifies Catecholamines Levels Present in Patients with Relapsing- Remitting Multiple Sclerosis.
Escribano BM, Aguilar-Luque M, Bahamonde C, Conde C, Lillo R, Sanchez-Lopez F, Giraldo AI, Cruz AH, Luque E, Gascon F, Aguera E, Tunez I. Escribano BM, et al. Among authors: Sanchez-Lopez F. Curr Pharm Des. 2016;22(31):4876-4880. doi: 10.2174/1381612822666160708000453. Curr Pharm Des. 2016. PMID: 27396595 Clinical Trial.
Experimental and Theoretical Approaches To Investigate the Immunogenicity of Taenia solium-Derived KE7 Antigen.
Bobes RJ, Navarrete-Perea J, Ochoa-Leyva A, Anaya VH, Hernández M, Cervantes-Torres J, Estrada K, Sánchez-Lopez F, Soberón X, Rosas G, Nunes CM, García-Varela M, Sotelo-Mundo RR, López-Zavala AA, Gevorkian G, Acero G, Laclette JP, Fragoso G, Sciutto E. Bobes RJ, et al. Among authors: Sanchez-Lopez F. Infect Immun. 2017 Nov 17;85(12):e00395-17. doi: 10.1128/IAI.00395-17. Print 2017 Dec. Infect Immun. 2017. PMID: 28923896 Free PMC article.
Effect of natalizumab on oxidative damage biomarkers in relapsing-remitting multiple sclerosis.
Tasset I, Bahamonde C, Agüera E, Conde C, Cruz AH, Pérez-Herrera A, Gascón F, Giraldo AI, Ruiz MC, Lillo R, Sánchez-López F, Túnez I. Tasset I, et al. Among authors: Sanchez-Lopez F. Pharmacol Rep. 2013;65(3):624-31. doi: 10.1016/s1734-1140(13)71039-9. Pharmacol Rep. 2013. PMID: 23950585 Free article.
Important role of oxidative stress biomarkers in Huntington's disease.
Túnez I, Sánchez-López F, Agüera E, Fernández-Bolaños R, Sánchez FM, Tasset-Cuevas I. Túnez I, et al. Among authors: Sanchez-Lopez F, Sanchez FM. J Med Chem. 2011 Aug 11;54(15):5602-6. doi: 10.1021/jm200605a. Epub 2011 Jul 7. J Med Chem. 2011. PMID: 21678912
Elevated melatonin levels in natalizumab-treated female patients with relapsing-remitting multiple sclerosis: relationship to oxidative stress.
Bahamonde C, Conde C, Agüera E, Lillo R, Luque E, Gascón F, Feijóo M, Cruz AH, Sánchez-López F, Túnez I. Bahamonde C, et al. Among authors: Sanchez-Lopez F. Eur J Pharmacol. 2014 May 5;730:26-30. doi: 10.1016/j.ejphar.2014.02.020. Epub 2014 Feb 25. Eur J Pharmacol. 2014. PMID: 24582759
29 results
Jump to page
Feedback